FDA Scientists Raise Questions About Duchenne Drug

(MedPage Today) -- FDA scientists said that investigational deramiocel, a stem cell treatment for Duchenne muscular dystrophy, did not meet its primary endpoint in a phase III trial, despite data presented at the American Academy of Neurology ...